Real-World Impact of Deep Targeted Sequencing on Erythrocytosis and Thrombocytosis Diagnosis: A Reference Centre Experience
Authors:
- Alberto Blanco-SánchezABAlberto Blanco-Sánchez
- Rodrigo Gil-MansoRGRodrigo Gil-Manso
- Rodrigo de NicolásRNRodrigo de Nicolás
- Nieves López-MuñozNLNieves López-Muñoz
- Rafael ColmenaresRCRafael Colmenares
- Reyes MasRMReyes Mas
- Ricardo SánchezRSRicardo Sánchez
- Inmaculada RapadoIRInmaculada Rapado
- Joaquín Martínez-LópezJoaquín Martínez-López
- Rosa Ayala DíazRDRosa Ayala Díaz
- Gonzalo Carreño-TarragonaGCGonzalo Carreño-Tarragona
Open Access
Abstract
Despite advances in diagnosis of erythrocytosis and thrombocytosis due to driver mutation testing, many cases remain classified as “idiopathic”. This can be explained by the absence of an evident secondary cause, inconclusive bone marrow biopsy or neglection of family history. Analysis of a broad panel of genes through next-generation sequencing (NGS) could improve diagnostic work-up identifying underlying genetic causes. We reviewed the results of NGS performed in our laboratory and its diagnostic impact on 117 patients with unexplained erythrocytosis and 58 with unexplained thrombocytosis; six patients (5.1%) were diagnosed with polycythaemia vera (PV) and 8 (6.8%) with familial erythrocytosis after NGS testing. Low EPO and a family history seemed to predict a positive result, respectively. However, a greater percentage of patients were ultimately diagnosed with secondary erythrocytosis (36%), remained as idiopathic (28.2%) or were self-limited (15%). The yield of NGS was shown to be slightly higher in patients with thrombocytosis, as 15 (25.9%) were diagnosed with essential thrombocythemia (ET) or familial thrombocytosis after variant detection; previous research has shown similar results, but most of them carried out NGS retrospectively, while the present study exhibits the performance of this test in a real-world setting. Overall, the low rate of variant detection and its poor impact on diagnostic work-up highlights the need for a thorough screening prior to NGS, in order to improve its yield.Keywords
Funding Information
- Instituto Carlos III (PI19/0518, PI22/1088)
- CRIS foundation (PI19/0518, PI22/1088)
- European Regional Development Fund (ERDF) (PI19/0518, PI22/1088)
This publication has 39 references indexed in Scilit:
- Diagnostic Approaches to Investigate JAK2-Unmutated Erythrocytosis Based on a Single Tertiary Center ExperienceMolecular Diagnosis & Therapy, 2024
- Variability of bone marrow biopsy reporting affects accuracy of diagnosis of myeloproliferative neoplasms: data from the ALLG MPN01 registryPathology, 2023
- Serum erythropoietin levels in 696 patients investigated for erythrocytosis with JAK2 mutation analysisAmerican Journal of Hematology, 2022
- Applications of next-generation sequencing in hematologic malignanciesHuman Immunology, 2021
- Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk‐stratification and managementAmerican Journal of Hematology, 2020
- Diagnosis of exon 12‐positive polycythemia vera rescued by NGSClinical Case Reports, 2020
- Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor statesThe Lancet Haematology, 2020
- Diagnostic and prognostic contribution of targeted NGS in patients with triple‐negative myeloproliferative neoplasmsAmerican Journal of Hematology, 2019
- Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in CancerThe Journal of Molecular Diagnostics, 2017
- Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteriaLeukemia, 2015